identify and capitalize on possible collaboration, strategic partnering, acquisition or divestiture opportunities

Exhibit 10.10(b)

Second Amendment to Exclusive Patent License Agreement
Between
University of Arizona and Oncothyreon, Inc.
Effective 15 September 2005

     This Second Amendment (“Second Amendment”), effective on the date of last authorized signature affixed hereto, is by and between the Arizona Board of Regents on behalf of the University of Arizona, having an office at 888 N. Euclid Avenue, Room 204, Tucson, Arizona 85721 (“LICENSOR”), and Oncothyreon, Inc., having its principal office at 2601 Fourth Avenue, Suite 500, Seattle, Washington 98121 (“LICENSEE”).

     WHEREAS, LICENSOR and Pro1X Pharmaceuticals Corporation, which was subsequently acquired by LICENSEE, entered into an Exclusive Patent License Agreement, effective 15 September 2005 (“Agreement”), that, by assignment of the Agreement, granted to LICENSEE exclusive rights in Licensed Patents described in Schedule A pursuant to Section 2.3 of the Agreement; and

     WHEREAS, LICENSOR and LICENSEE previously amended Schedule A of the Agreement to add certain Licensed Patents to the Agreement pursuant to the First Amendment to the Agreement, which amendment was effective on 28 November 2008 (“First Amendment”); and

     WHEREAS, LICENSOR and LICENSEE wish to further amend Schedule A of the Agreement to delete certain Licensed Patents from the Agreement.

     NOW, THEREFORE, the parties agree as follows:

     1. Schedule A (as amended by the First Amendment) shall be replaced in its entirety as follows:

Schedule A

Serial No.		Territory		Title		Filing Date		Status
10/288,888		US		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/6/2002		Abandoned
10/929,156		US		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		8/20/2004		Pending
2003291282		AU		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
2504496		CA		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending

Serial No.		Territory		Title		Filing Date		Status
03768672.2		EP		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
2004-551738		JP		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
2005-004845		MX		N-Oxides and Derivatives of Melphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
PCT/US03/35266		PCT		N-Oxides and Derivatives of IVielphalan for Treating Diseased States Associated With Hypoxia Inducible Factor		11/3/2003		Pending
60/487,562		US		Regulation of HIF Protein Levels via Deubiquination Pathway		7/14/2003		Expired
PCT/US04/22656		PCT		Regulation of HIF Protein Levels via Deubiquination Pathway		7/14/2004		Pending
60/602,151		US		Method of Pre-selecting Patients for Anti-VEGF, Anti-H1F-1 or Anti-Thioredoxin Therapy		8/17/2004		Expired
60/602,163		US		Monitoring Effects of PX-12 on Tumor Vascular Permeability		8/17/2004		Expired
11/206,526		US		Method of Preselecting Patients for Anti-VEGF, Anti-H1F-1 or Anti-Thioredoxin Therapy		8/17/2005		Pending
PCT/US05/29416		PCT		Method of Preselection Patients for Anti-VEGF, Anti- H1F-1 or Anti-Thioredoxin Therapy		8/17/2005		Reg./nat. Phases entered
2005277350		AU		Method of Preselection Patients for Anti-VEGF, Anti-H1F-1 or Anti-Thioredoxin Therapy		8/17/2005		Pending
2,577,312		CA		Method of Preselection Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy		8/17/2005		Pending
05808798.2		EP		Method of Preselection Patients for Anti-VEGF, Anti-HIF-1 or Anti-Thioredoxin Therapy		8/17/2005		Pending

     2. All other terms of the Agreement shall remain the same.

[signature page follows]

     IN WITNESS WHEREOF, a duly authorized officer of each party hereto has executed this Second Amendment in duplicate originals by on the day and year below written.

ARIZONA BOARD OF REGENTS On behalf of THE UNIVERSITY OF ARIZONA				ONCOTHYREON, INC.
By:		/s/ Patrick L. Jones, PhD, MBA		By:		/s/ Robert L. Kirkman, MD
		Name: Patrick L. Jones, PhD, MBA				Name: Robert L. Kirkman, MD
		Title:   Director, Office of Technology Transfer				Title:   President and CEO
Date: 12th July 2010				Date: 13th August 2010